Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 303

1.

ISGE statement on oral emergency contraception.

Glasier A, Gemzell-Danielsson K, Bouchard P, Genazzani AR, Al-Azzawi F, Berga S, Birkhaeuser M, Brincat M, De Melo NR, Foidart JM, Kenemans P, Lunenfeld B, Maruo T, Milewicz A, Naftolin F, Ng EH, Schindler A, Simon C, Simoncini T, Simpson E, Siseles N, Smetnik V, Tarlatzis B, von Schoultz B.

Gynecol Endocrinol. 2014 Oct;30(10):681-2. doi: 10.3109/09513590.2014.950649. Review.

PMID:
25242337
2.

Androgens and breast cancer risk.

Kenemans P, van der Mooren MJ.

Gynecol Endocrinol. 2012 Mar;28 Suppl 1:46-9. doi: 10.3109/09513590.2012.651925. Review.

PMID:
22394304
3.

Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy.

Bundred NJ, Kenemans P, Yip CH, Beckmann MW, Foidart JM, Sismondi P, Schoultz Bv, Vassilopoulou-Sellin R, Galta RE, Lieshout EV, Mol-Arts M, Planellas J, Kubista E.

Breast Cancer Res. 2012 Jan 17;14(1):R13.

4.

Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients--data from LIBERATE trial.

Sismondi P, Kimmig R, Kubista E, Biglia N, Egberts J, Mulder R, Planellas J, Moggio G, Mol-Arts M, Kenemans P.

Maturitas. 2011 Dec;70(4):365-72. doi: 10.1016/j.maturitas.2011.09.003. Epub 2011 Oct 26.

PMID:
22030384
5.

Less mammographic density after nasal versus oral administration of postmenopausal hormone therapy.

van Dijck JA, Otten JD, Karssemeijer N, Kenemans P, Verbeek AL, van der Mooren MJ.

Climacteric. 2011 Dec;14(6):683-8. doi: 10.3109/13697137.2011.586752. Epub 2011 Sep 26.

PMID:
21942620
6.

Serum testosterone levels measured by isotope dilution-liquid chromatography-tandem mass spectrometry in postmenopausal women versus those in women who underwent bilateral oophorectomy.

Bui HN, Struys EA, Martens F, de Ronde W, Thienpont LM, Kenemans P, Verhoeven MO, Jakobs C, Dijstelbloem HM, Blankenstein MA.

Ann Clin Biochem. 2010 May;47(Pt 3):248-52. doi: 10.1258/acb.2010.009171. Epub 2010 Apr 20.

PMID:
20406776
7.

Tibolone revisited: still a good treatment option for healthy, early postmenopausal women.

Kenemans P.

Gynecol Endocrinol. 2010 Apr;26(4):237-9. doi: 10.3109/09513590903507339. No abstract available.

PMID:
20017707
8.

Therapeutic options for postmenopausal female sexual dysfunction.

Al-Azzawi F, Bitzer J, Brandenburg U, Castelo-Branco C, Graziottin A, Kenemans P, Lachowsky M, Mimoun S, Nappi RE, Palacios S, Schwenkhagen A, Studd J, Wylie K, Zahradnik HP.

Climacteric. 2010 Apr;13(2):103-20. doi: 10.3109/13697130903437615. Review.

PMID:
19958161
9.

Oncogenic pathways in hereditary and sporadic breast cancer.

Kenemans P, Verstraeten RA, Verheijen RH.

Maturitas. 2008 Sep-Oct;61(1-2):141-50.

PMID:
19434886
10.

Menopause, hormones and sex: the role of the doctor.

Palacios S, Kenemans P.

Maturitas. 2009 Jun 20;63(2):105-6. doi: 10.1016/j.maturitas.2009.02.013. Epub 2009 Apr 1. No abstract available.

PMID:
19342186
11.

Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial.

Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, Mulder R, van Os S, Beckmann MW; LIBERATE Study Group.

Lancet Oncol. 2009 Feb;10(2):135-46. doi: 10.1016/S1470-2045(08)70341-3. Epub 2009 Jan 23.

12.

Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: a randomised controlled trial.

de Kraker AT, Kenemans P, Smolders RG, Kroeks MV, van der Mooren MJ.

Eur J Obstet Gynecol Reprod Biol. 2009 Feb;142(2):139-44. doi: 10.1016/j.ejogrb.2008.10.007. Epub 2008 Dec 17.

PMID:
19095343
13.

The prognostic and clinical value of morphometry and DNA cytometry in borderline ovarian tumors: a prospective study.

Verbruggen MB, van Diest PJ, Baak JP, Broeckaert MA, Kenemans P, Verheijen RH.

Int J Gynecol Pathol. 2009 Jan;28(1):35-40. doi: 10.1097/PGP.0b013e31818131ff.

PMID:
19047910
14.

SCC-Ag, lymph node metastases and sentinel node procedure in early stage squamous cell cervical cancer.

van de Lande J, Davelaar EM, von Mensdorff-Pouilly S, Water TJ, Berkhof J, van Baal WM, Kenemans P, Verheijen RH.

Gynecol Oncol. 2009 Jan;112(1):119-25. doi: 10.1016/j.ygyno.2008.09.042. Epub 2008 Nov 12.

PMID:
19007978
15.

The influence of physiological and surgical menopause on coronary heart disease risk markers.

Verhoeven MO, van der Mooren MJ, Teerlink T, Verheijen RH, Scheffer PG, Kenemans P.

Menopause. 2009 Jan-Feb;16(1):37-49. doi: 10.1097/gme.0b013e31817c42d6.

PMID:
18791484
16.

Endometrial effects of tibolone in elderly, osteoporotic women.

Ettinger B, Kenemans P, Johnson SR, Mol-Arts M, Van Os S, Seifert W, Verweij PJ, Cummings SR.

Obstet Gynecol. 2008 Sep;112(3):653-9. doi: 10.1097/AOG.0b013e3181809e25.

PMID:
18757665
17.

The effects of tibolone in older postmenopausal women.

Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, Bilezikian J, Kerzberg EM, Johnson S, Zanchetta J, Grobbee DE, Seifert W, Eastell R; LIFT Trial Investigators.

N Engl J Med. 2008 Aug 14;359(7):697-708. doi: 10.1056/NEJMoa0800743.

18.

Estrogenic uterovaginal effects of oral estetrol in the modified Allen-Doisy test.

Heegaard AM, Holinka CF, Kenemans P, Coelingh Bennink HJ.

Climacteric. 2008;11 Suppl 1:22-8. doi: 10.1080/13697130701842490.

PMID:
18464018
19.

A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer.

Davelaar EM, van de Lande J, von Mensdorff-Pouilly S, Blankenstein MA, Verheijen RH, Kenemans P.

Tumour Biol. 2008;29(1):9-17. doi: 10.1159/000132566. Epub 2008 May 23.

PMID:
18497544
20.

Breast cancer risk in postmenopausal women using testosterone in combination with hormone replacement therapy.

Bitzer J, Kenemans P, Mueck AO; FSDeducation Group.

Maturitas. 2008 Mar 20;59(3):209-18. doi: 10.1016/j.maturitas.2008.01.005. Epub 2008 Mar 14. Review.

PMID:
18343056
21.

Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients--design and baseline data 'LIBERATE' trial.

Kenemans P, Kubista E, Foidart JM, Yip CH, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Beckmann MW, Bundred NJ, Egberts J, van Os S, Planellas J.

Breast. 2007 Dec;16 Suppl 2:S182-9. Erratum in: Breast. 2008 Apr;17(2):214-5. Egberts, J [added]; van Os, S [added]; Planellas, J [added].

22.

Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review.

Hemelaar M, van der Mooren MJ, Rad M, Kluft C, Kenemans P.

Fertil Steril. 2008 Sep;90(3):642-72. Epub 2007 Oct 17. Review.

PMID:
17923128
23.

Quality of life in breast cancer patients.

Kenemans P.

Gynecol Endocrinol. 2007 Jul;23(7):366-7. No abstract available.

PMID:
17701765
24.

Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial.

Hemelaar M, Kenemans P, Hack CE, Klipping C, van der Mooren MJ.

Menopause. 2008 Mar-Apr;15(2):248-55.

PMID:
17693902
25.

High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC).

Moreno M, Bontkes HJ, Scheper RJ, Kenemans P, Verheijen RH, von Mensdorff-Pouilly S.

Cancer Lett. 2007 Nov 8;257(1):47-55. Epub 2007 Aug 9.

PMID:
17692456
26.

Ovarian carcinogenesis, an alternative theory.

Piek JM, Kenemans P, Zweemer RP, van Diest PJ, Verheijen RH.

Gynecol Oncol. 2007 Nov;107(2):355. Epub 2007 Aug 9. No abstract available.

PMID:
17692366
27.

Breast cancer and climacteric complaints: weighing up risks of hormone therapy against quality of life.

Franke HR, Brood-van Zanten MM, Burger CW, van der Mooren MJ, Kenemans P.

Eur J Obstet Gynecol Reprod Biol. 2007 Oct;134(2):143-6. Epub 2007 Jun 18. Review.

PMID:
17574325
28.

Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation.

Hermsen BB, Verheijen RH, Menko FH, Gille JJ, van Uffelen K, Blankenstein MA, Meijer S, van Diest PJ, Kenemans P, von Mensdorff-Pouilly S.

Eur J Cancer. 2007 Jul;43(10):1556-63. Epub 2007 May 25.

PMID:
17532207
29.

Effects of a supplement containing isoflavones and Actaea racemosa L. on asymmetric dimethylarginine, lipids, and C-reactive protein in menopausal women.

Verhoeven MO, Teerlink T, Kenemans P, Zuijdgeest-van Leeuwen SD, van der Mooren MJ.

Fertil Steril. 2007 Apr;87(4):849-57.

PMID:
17430734
30.

Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.

Hermsen BB, von Mensdorff-Pouilly S, Berkhof J, van Diest PJ, Gille JJ, Menko FH, Blankenstein MA, Kenemans P, Verheijen RH.

J Clin Oncol. 2007 Apr 10;25(11):1383-9.

PMID:
17416858
31.
32.

Effects of intranasal versus oral hormone therapy on asymmetric dimethylarginine in healthy postmenopausal women: a randomized study.

Verhoeven MO, Hemelaar M, Teerlink T, Kenemans P, van der Mooren MJ.

Atherosclerosis. 2007 Nov;195(1):181-8. Epub 2006 Nov 7.

PMID:
17084844
33.

BRCA1 and p53 protein expression in cultured ovarian surface epithelial cells derived from women with and without a BRCA1 germline mutation.

Piek JM, Dorsman JC, Massuger LF, Ansink AC, Weegenaar J, Shvarts A, Kenemans P, Verheijen RH.

Arch Gynecol Obstet. 2006 Oct;274(6):327-31. Epub 2006 Jul 7.

PMID:
16826413
34.

Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women.

Hemelaar M, Rosing J, Kenemans P, Thomassen MC, Braat DD, van der Mooren MJ.

Arterioscler Thromb Vasc Biol. 2006 Jul;26(7):1660-6. Epub 2006 Apr 27.

PMID:
16645152
35.

Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer.

Hermsen BB, van Diest PJ, Berkhof J, Menko FH, Gille JJ, Piek JM, Meijer S, Winters HA, Kenemans P, Mensdorff-Pouilly Sv, Verheijen RH.

Int J Cancer. 2006 Sep 15;119(6):1412-8.

36.

Intranasal continuous combined 17 beta-estradiol/norethisterone therapy improves the lipid profile in healthy postmenopausal women.

Hemelaar M, Kenemans P, de Bie L, van de Weijer PH, van der Mooren MJ.

Fertil Steril. 2006 Apr;85(4):979-88.

PMID:
16580384
37.

No increase in C-reactive protein levels during intranasal compared to oral hormone therapy in healthy post-menopausal women.

Hemelaar M, Kenemans P, Schalkwijk CG, Braat DD, van der Mooren MJ.

Hum Reprod. 2006 Jun;21(6):1635-42. Epub 2006 Feb 24.

PMID:
16501036
38.

Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women.

Vogelvang TE, van der Mooren MJ, Mijatovic V, Kenemans P.

Drugs. 2006;66(2):191-221. Review.

PMID:
16451093
39.

Oral, more than transdermal, oestrogen therapy lowers asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo-controlled study.

Verhoeven MO, Hemelaar M, van der Mooren MJ, Kenemans P, Teerlink T.

J Intern Med. 2006 Feb;259(2):199-208.

40.
41.

Effects of transdermal and oral postmenopausal hormone therapy on vascular function: a randomized, placebo-controlled study in healthy postmenopausal women.

Hemelaar M, van der Mooren MJ, van Baal WM, Schalkwijk CG, Kenemans P, Stehouwer CD.

Menopause. 2005 Sep-Oct;12(5):526-35. Epub 2005 Sep 1.

PMID:
16145306
42.

Effect of a combination of isoflavones and Actaea racemosa Linnaeus on climacteric symptoms in healthy symptomatic perimenopausal women: a 12-week randomized, placebo-controlled, double-blind study.

Verhoeven MO, van der Mooren MJ, van de Weijer PH, Verdegem PJ, van der Burgt LM, Kenemans P; CuraTrial Research Group.

Menopause. 2005 Jul-Aug;12(4):412-20. Epub 2005 Jul 21.

PMID:
16037756
43.

Postmenopausal hormone therapy and breast cancer: what is the problem?

Kenemans P.

Maturitas. 2005 May 16;51(1):75-82. Review.

PMID:
15883112
44.

Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group.

Kenemans P, Speroff L; International Tibolone Consensus Group.

Maturitas. 2005 May 16;51(1):21-8.

PMID:
15883105
45.

Practical guidelines for postmenopausal hormone therapy.

Speroff L, Kenemans P, Burger HG.

Maturitas. 2005 May 16;51(1):4-7.

PMID:
15883102
46.

Women's health after WHI.

Kenemans P.

Maturitas. 2005 May 16;51(1):1-3. No abstract available.

PMID:
15883101
47.

Lobulitis is a frequent finding in prophylactically removed breast tissue from women at hereditary high risk of breast cancer.

Hermsen BB, von Mensdorff-Pouilly S, Fabry HF, Winters HA, Kenemans P, Verheijen RH, van Diest PJ.

J Pathol. 2005 Jun;206(2):220-3.

PMID:
15880615
48.

Endothelium-dependent dilatory effects of 3alpha-OH-tibolone in gracilis muscle arterioles of the female Wistar rat.

Korstjens IJ, Smolders RG, van der Mooren MJ, Kloosterboer HJ, Kenemans P, Sipkema P.

Menopause. 2005 May-Jun;12(3):340-7.

PMID:
15879924
49.

Different effects of low-dose transdermal and oral oestrogen therapy on procarboxy-peptidase U, an inhibitor of fibrinolysis, in healthy postmenopausal women: a randomised, placebo-controlled study.

Post MS, Leurs JR, van der Mooren MJ, van Baal WM, Hendriks DF, Stehouwer CD, Kenemans P.

Thromb Haemost. 2005 Mar;93(3):620-2. No abstract available.

PMID:
15735823
50.

Oral estradiol decreases plasma homocysteine, vitamin B6, and albumin in postmenopausal women but does not change the whole-body homocysteine remethylation and transmethylation flux.

Smolders RG, de Meer K, Kenemans P, Jakobs C, Kulik W, van der Mooren MJ.

J Clin Endocrinol Metab. 2005 Apr;90(4):2218-24. Epub 2005 Jan 25.

PMID:
15671107

Supplemental Content

Loading ...
Support Center